Aura Biosciences rises on early-stage data for bladder cancer drug

Aura Biosciences

18/10/2024 17:24

** Cancer drug developer Aura Biosciences'  AURA.O  shares
rise 15% to $11.84
    ** Company reports interim data from early-stage trial of
experimental cancer drug, bel-sar, to treat patients with
non-muscle-invasive bladder cancer
    ** Aura says bel-sar was well tolerated and four of five
patients with low-grade disease showed complete clinical
responses to treatment with the drug with no tumor cells
remaining
    ** At least three brokerages raise PT on company's shares
    ** Leerink Partners ("outperform") raises PT to $22 from $19
    ** "Data are in small patient numbers, but we are encouraged
by early signs of robust efficacy and potential differentiation
from competitors" - brokerage
    ** H.C. Wainwright ("buy") also raises PT to $22 from $21
    ** Avg rating of analysts covering AURA is "buy"; median PT
$22 - LSEG 
    ** Including session's gains, stock up 16% YTD

 (Reporting by Sukriti Gupta in Bengaluru)
 ((Sukriti.Gupta@thomsonreuters.com))